Ex Vivo Programming of Dendritic Cells by Mitochondria-Targeted Nanoparticles to Produce Interferon-Gamma for Cancer Immunotherapy

被引:120
|
作者
Marrache, Sean [1 ]
Tundup, Smanla [3 ]
Harn, Donald A. [3 ]
Dhar, Shanta [1 ,2 ]
机构
[1] Univ Georgia, Dept Chem, NanoTherapeut Res Lab, Athens, GA 30602 USA
[2] Univ Georgia, Dept Physiol & Pharmacol, Athens, GA 30602 USA
[3] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA
基金
美国国家卫生研究院;
关键词
vaccine; photodynamic therapy; dendritic cell therapy; biodegradable polymer; apoptosis; HUMAN T-CELLS; ANTITUMOR IMMUNITY; PHOTODYNAMIC THERAPY; IN-VIVO; BREAST-CANCER; DELIVERY; IL-18; CHEMOTHERAPY; ACTIVATION; SYNERGIZES;
D O I
10.1021/nn403158n
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
One of the limitations for clinical applications of dendritic cell (DO-based cancer immunotherapy is the low potency in generating tumor antigen specific T cell responses. We examined the immunotherapeutic potential of a mitochondria-targeted nanoparticle (NP) based on a biodegradable polymer and zinc phthalocyanine (ZnPc) photosensitizer (T-ZnPc-NPs). Here, we report that tumor antigens generated from treatment of breast cancer cells with T-ZnPc-NPs upon light stimulation activate DCs to produce high levels of Interferon-gamma, an important cytokine considered as a product of T and natural killer cells. The remarkable ex vivo DC stimulation ability of this tumor cell supernatant is a result, of an interleukin (IL)-12/IL-18 autocrine effect These findings contribute to the understanding of how in situ light activation amplifies the host immune responses when NPs deliver the photosensitizer to the mitochondria and open up the possibility of using mitochondria-targeted-NP-treated, light activated cancer cell supernatants as possible vaccines.
引用
收藏
页码:7392 / 7402
页数:11
相关论文
共 7 条
  • [1] Mitochondria-Targeted Hydroxyapatite Nanoparticles for Selective Growth Inhibition of Lung Cancer in Vitro and in Vivo
    Sun, Yi
    Chen, Yaying
    Ma, Xiaoyu
    Yuan, Yuan
    Liu, Changsheng
    Kohn, Joachim
    Qian, Jiangchao
    ACS APPLIED MATERIALS & INTERFACES, 2016, 8 (39) : 25680 - 25690
  • [2] Magnetic response of mitochondria-targeted cancer cells with bacterial magnetic nanoparticles
    Choi, Jungin
    Shin, Jaeha
    Lee, Junghoon
    Cha, Misun
    CHEMICAL COMMUNICATIONS, 2012, 48 (60) : 7474 - 7476
  • [3] Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival
    Cornforth, A. N.
    Fowler, A. W.
    Carbonell, D. J.
    Dillman, R. O.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (01) : 123 - 131
  • [4] Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation
    Akita, Hidetaka
    Kogure, Kentaro
    Moriguchi, Rumiko
    Nakamura, Yoshio
    Higashi, Tomoko
    Nakamura, Takashi
    Serada, Satoshi
    Fujimoto, Minoru
    Naka, Tetsuji
    Futaki, Shiroh
    Harashima, Hideyoshi
    JOURNAL OF CONTROLLED RELEASE, 2010, 143 (03) : 311 - 317
  • [5] Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival
    A. N. Cornforth
    A. W. Fowler
    D. J. Carbonell
    R. O. Dillman
    Cancer Immunology, Immunotherapy, 2011, 60 : 123 - 131
  • [6] Reprint of: Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation
    Akita, Hidetaka
    Kogure, Kentaro
    Moriguchi, Rumiko
    Nakamura, Yoshio
    Higashi, Tomoko
    Nakamura, Takashi
    Serada, Satoshi
    Fujimoto, Minoru
    Naka, Tetsuji
    Futaki, Shiroh
    Harashima, Hideyoshi
    JOURNAL OF CONTROLLED RELEASE, 2011, 149 (01) : 58 - 64
  • [7] LL-37 as a Powerful Molecular Tool for Boosting the Performance of Ex Vivo-Produced Human Dendritic Cells for Cancer Immunotherapy
    Stakheev, Dmitry
    Taborska, Pavla
    Kalkusova, Katerina
    Bartunkova, Jirina
    Smrz, Daniel
    PHARMACEUTICS, 2022, 14 (12)